Bictegravir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Using the provided Evidence Pack, here is the drug repurposing evaluation report. Note: taiwan_regulatory data (not Norway) was used for the market-status sections, since the underlying dataset is Taiwan-specific (TFDA, "TW-DB11799").
Bictegravir: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Bictegravir (as part of the fixed-dose combination Biktarvy) is an integrase strand transfer inhibitor internationally used for HIV-1 infection, though it is not currently registered in Taiwan and drug-level indication/MOA data are not available in this evidence pack. The TxGNN model predicts it may be effective for Feline Acquired Immunodeficiency Syndrome, but this top-ranked prediction currently has no supporting clinical trials or literature — evidence exists only for a closely related, similarly-scored prediction (simian immunodeficiency virus infection).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Taiwan regulatory data (no licenses on file); internationally, bictegravir is used for HIV-1 infection as part of Biktarvy |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature identified) |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (blocking data gap, DG002). Based on known pharmacology, bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI), marketed internationally as a component of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) for HIV-1 infection. It is not currently registered or marketed in Taiwan.
The top-ranked predicted indication, feline acquired immunodeficiency syndrome, is caused by feline immunodeficiency virus (FIV) — a lentivirus structurally and mechanistically related to HIV, also dependent on a viral integrase to insert its genome into host DNA. This provides a plausible mechanistic rationale (cross-lentivirus integrase inhibition) for the TxGNN prediction, even though no dedicated FIV/veterinary study data exists to confirm it.
Notably, a second, equally-scored prediction — simian immunodeficiency virus (SIV) infection — is supported by actual literature (see below) describing bictegravir's in vitro antiviral activity against SIV and INSTI-resistant HIV-1 strains in nonhuman primate models. While SIV infection is not a human clinical indication, this literature strengthens the underlying biological plausibility that bictegravir's integrase-inhibition mechanism extends across related lentiviruses, indirectly supporting (but not proving) the feline AIDS prediction. Both predicted indications are non-human/veterinary in nature, which is an important caveat for a human drug repurposing evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available for the top-ranked prediction (feline acquired immunodeficiency syndrome).
For context, the closely related, equally-scored prediction ("simian immunodeficiency virus infection," rank 2) is supported by 3 publications on bictegravir's antiviral activity against SIV/HIV-1 integrase-inhibitor-resistant strains (PMID 28923862, 32506843, 39559349), all preclinical/mechanistic in nature — none are human RCTs.
Taiwan Market Information
Bictegravir is not currently marketed in Taiwan; no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (feline acquired immunodeficiency syndrome) has zero supporting clinical trials or literature (L5), targets a non-human/veterinary condition rather than a human indication, and the drug carries a blocking data gap on TFDA warnings/contraindications (DG001) plus a high-impact MOA data gap (DG002) — together insufficient to support any human repurposing decision.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) to clear the blocking safety data gap
- Confirmed MOA data from DrugBank
- Clarification of whether a human-relevant analog indication exists (e.g., retroviral/lentiviral disease in humans), since current top predictions are veterinary/nonhuman
- If pursuing the feline AIDS or SIV angle, this would need to be reframed as a veterinary drug repurposing evaluation rather than a human one
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.